Stock listing
NASDAQ:ENLV Enlivex Ltd. Stock
Home listing (NASDAQ) of Enlivex Ltd.
Follow Enlivex Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:ENLV
$1.05 USD -0.15 (-12.5%)
Close on Nov 20, 2026
- Day range
- $1.05 – $1.22 USDNov 20, 2026
- Volume
- 39,970 sharesNov 20, 2026
- Market cap
- $1.61M USDAt the close on Nov 20, 2026 · price × 1.53M shares outstanding
- 52-week range
- $1.00 – $434.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $45,475 USDMedian day 2,465 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ENLV · Home | $1.05 USD | -0.15 (-12.5%) | 39,970 | $1.15 | $1.22 | $1.05 | $1.20 | Close on Nov 20, 2026 |
| Frankfurt:1BT | €1.05 EUR | +0.02 (+1.9%) | — | €1.05 | €1.05 | €1.05 | €1.03 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ENLV · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.05 | -0.15 | -12.5% | $1.15 | $1.22 | $1.05 | 39,970 | |
| $1.20 | +0.05 | +4.3% | $1.18 | $1.29 | $1.16 | 39,667 | |
| $1.15 | +0.03 | +2.7% | $1.15 | $1.18 | $1.11 | 18,949 | |
| $1.12 | -0.07 | -5.9% | $1.09 | $1.13 | $1.00 | 65,712 | |
| $1.19 | -0.055 | -4.4% | $1.30 | $1.312 | $1.18 | 22,272 | |
| $1.245 | -0.015 | -1.2% | $1.25 | $1.338 | $1.19 | 20,750 | |
| $1.26 | +0.06 | +5.0% | $1.20 | $1.27 | $1.18 | 41,040 | |
| $1.20 | -0.17 | -12.4% | $1.35 | $1.35 | $1.20 | 47,127 | |
| $1.37 | +0.10 | +7.9% | $1.28 | $1.41 | $1.28 | 20,860 | |
| $1.27 | 0.00 | 0.0% | $1.27 | $1.30 | $1.23 | 18,131 | |
| $1.27 | -0.12 | -8.6% | $1.38 | $1.40 | $1.22 | 47,035 | |
| $1.39 | -0.07 | -4.8% | $1.44 | $1.46 | $1.37 | 24,093 | |
| $1.46 | +0.05 | +3.5% | $1.43 | $1.56 | $1.43 | 37,948 | |
| $1.41 | -0.37 | -20.8% | $1.87 | $1.87 | $1.40 | 137,600 | |
| $1.78 | -0.76 | -29.9% | $2.47 | $2.47 | $1.73 | 128,298 | |
| $2.54 | -0.07 | -2.7% | $2.62 | $2.76 | $2.46 | 49,834 | |
| $2.61 | -0.09 | -3.3% | $2.71 | $2.765 | $2.55 | 36,323 | |
| $2.70 | +0.097 | +3.7% | $2.56 | $2.89 | $2.215 | 80,489 | |
| $2.603 | -0.171 | -6.2% | $2.774 | $2.798 | $2.562 | 26,483 | |
| $2.774 | -0.413 | -13.0% | $2.704 | $2.93 | $2.704 | 2,574 | |
| $3.187 | -0.048 | -1.5% | $3.138 | $3.278 | $3.075 | 2,051 | |
| $3.235 | -0.344 | -9.6% | $3.566 | $3.677 | $3.20 | 2,913 | |
| $3.579 | +0.261 | +7.9% | $3.44 | $3.666 | $3.282 | 1,748 | |
| $3.318 | +0.038 | +1.2% | $3.379 | $3.638 | $3.08 | 2,373 | |
| $3.28 | -0.307 | -8.6% | $3.685 | $3.734 | $3.272 | 1,874 | |
| $3.587 | +0.138 | +4.0% | $3.523 | $3.773 | $3.36 | 2,189 | |
| $3.45 | -0.109 | -3.1% | $3.595 | $3.648 | $3.36 | 2,176 | |
| $3.558 | -0.49 | -12.1% | $4.144 | $4.152 | $3.539 | 3,414 | |
| $4.048 | -0.016 | -0.4% | $4.16 | $4.214 | $3.926 | 3,488 | |
| $4.064 | -0.368 | -8.3% | $4.00 | $4.522 | $3.584 | 10,874 | |
| $4.432 | -0.47 | -9.6% | $5.312 | $6.88 | $4.085 | 127,659 | |
| $4.902 | -0.541 | -9.9% | $5.624 | $5.627 | $4.80 | 15,230 | |
| $5.443 | -0.349 | -6.0% | $5.979 | $6.046 | $5.437 | 1,600 | |
| $5.792 | -0.405 | -6.5% | $6.40 | $6.528 | $5.771 | 1,659 | |
| $6.197 | -0.566 | -8.4% | $6.789 | $6.878 | $6.08 | 2,465 | |
| $6.763 | -1.282 | -15.9% | $7.872 | $8.029 | $6.582 | 2,956 | |
| $8.045 | +0.363 | +4.7% | $7.696 | $9.28 | $7.522 | 3,798 | |
| $7.682 | -0.542 | -6.6% | $8.32 | $8.48 | $7.52 | 2,296 | |
| $8.224 | -1.336 | -14.0% | $9.60 | $9.60 | $8.043 | 2,465 | |
| $9.56 | -0.131 | -1.4% | $9.60 | $9.92 | $9.28 | 1,240 | |
| $9.691 | -0.549 | -5.4% | $10.14 | $10.24 | $9.12 | 1,489 | |
| $10.24 | -0.102 | -1.0% | $10.13 | $11.00 | $9.842 | 2,321 | |
| $10.34 | -0.742 | -6.7% | $11.04 | $11.34 | $9.179 | 4,821 | |
| $11.08 | -1.821 | -14.1% | $13.44 | $13.60 | $10.64 | 2,621 | |
| $12.91 | +1.27 | +10.9% | $11.68 | $13.10 | $11.37 | 1,368 | |
| $11.64 | -1.342 | -10.3% | $13.14 | $13.62 | $10.24 | 2,999 | |
| $12.98 | -1.146 | -8.1% | $14.40 | $14.72 | $12.64 | 1,604 | |
| $14.12 | +0.291 | +2.1% | $14.08 | $14.72 | $13.92 | 896 | |
| $13.83 | -1.52 | -9.9% | $15.20 | $16.32 | $13.82 | 1,190 | |
| $15.35 | -0.339 | -2.2% | $16.00 | $17.12 | $15.20 | 1,000 | |
| $15.69 | -0.949 | -5.7% | $16.48 | $16.96 | $15.68 | 1,100 | |
| $16.64 | -1.12 | -6.3% | $17.92 | $19.47 | $16.32 | 1,124 | |
| $17.76 | +0.16 | +0.9% | $17.60 | $19.04 | $16.96 | 744 | |
| $17.60 | -0.96 | -5.2% | $18.40 | $18.56 | $16.32 | 985 | |
| $18.56 | -1.44 | -7.2% | $20.00 | $20.40 | $18.08 | 1,148 | |
| $20.00 | -0.48 | -2.3% | $20.64 | $20.80 | $19.36 | 889 | |
| $20.48 | 0.00 | 0.0% | $20.32 | $20.96 | $19.20 | 1,341 | |
| $20.48 | -1.12 | -5.2% | $21.28 | $21.44 | $18.40 | 1,577 | |
| $21.60 | -2.00 | -8.5% | $24.00 | $25.20 | $21.52 | 2,075 | |
| $23.60 | -0.64 | -2.6% | $24.16 | $26.56 | $23.52 | 2,028 | |
| $24.24 | -0.08 | -0.3% | $24.32 | $25.92 | $23.36 | 585 | |
| $24.32 | +0.16 | +0.7% | $23.84 | $25.12 | $23.36 | 635 | |
| $24.16 | +0.64 | +2.7% | $23.68 | $24.96 | $23.04 | 581 | |
| $23.52 | -0.48 | -2.0% | $23.84 | $24.32 | $22.24 | 615 | |
| $24.00 | -3.68 | -13.3% | $26.88 | $27.20 | $23.28 | 1,058 |
Splits
4 splits since 2017 · NASDAQ:ENLV · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-16 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-8 | Consolidation | |
| 1-for-5 | Consolidation |
- Ticker
- NASDAQ:ENLV
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
Latest deck · Jun 24, 2026
Investor Presentation (June 2026)
Investor deck · 25 slides
Latest news
Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
Nov 18, 2026
Closed $1.20 (+4.3%) on Nov 18, 2026
Enlivex Announces Pricing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nov 16, 2026
Closed $1.12 (-5.9%) on Nov 16, 2026
Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
Nov 2, 2026
Closed $1.41 (-20.8%) on Nov 2, 2026
Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Oct 28, 2026
Closed $2.61 (-3.3%) on Oct 28, 2026
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
Oct 27, 2026
Closed $2.70 (+3.7%) on Oct 27, 2026
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Oct 22, 2026
Closed $2.77 (-13.0%) on Oct 23, 2026
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Sep 22, 2026
Closed $10.34 (-6.7%) on Sep 22, 2026
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
Jul 30, 2026
Closed $31.20 (-13.3%) on Jul 30, 2026
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
Jul 29, 2026
Closed $36.00 (+0.4%) on Jul 29, 2026
Enlivex Announces $400,000,000 Private Placement
Jul 28, 2026
Closed $35.84 (-47.4%) on Jul 28, 2026
Enlivex Ltd. on 6ix
- News releases
- 37 in the last 12 months · 151 in all · newest Nov 18, 2026 · oldest 2019
- Decks
- 32 decks · latest Jun 24, 2026
Where Enlivex Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ENLV · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A119KH | LS Exchange | Germany | EUR |
| Lang & Schwarz:A119KH | Lang & Schwarz | Germany | EUR |
| Frankfurt:1BT | Frankfurt | Germany | EUR |
| Tradegate:1BT | Tradegate | Germany | EUR |
| BOATS:ENLV | BOATS | United States | USD |
| Stuttgart:1BT | Stuttgart | Germany | EUR |
Valuation
Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $13.34M USD
- P/E
- 0.0×
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.67
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 1280.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -18.40 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Oren Hershkovitz | Chief Executive Officer |
| Shachar Shlosberger | Chief Financial Officer |
| Veronique Amor-Baroukh | Chief Operating Officer |
| Einat Galamidi | Chief Medical Officer |
| Shai Novik | Executive Chairman |
Board
| Director | Role |
|---|---|
| Shai Novik | Executive Chairman |
| Matteo Renzi | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 20, 2026 | |
| Q2 2026 | Sep 25, 2026 · After close | −14.0% |
| Q1 2026 | Jun 26, 2026 | −0.1% |
| Q4 2025 | Mar 25, 2026 · Before open | +9.1% |
| Q3 2025 | Nov 14, 2025 · After close | −1.6% |
| Q2 2025 | Aug 29, 2025 · After close | +0.9% |
| Q1 2025 | May 30, 2025 · After close | +0.4% |
| Q4 2024 | Mar 31, 2025 | −6.9% |
| Q3 2024 | Nov 29, 2024 · After close | −5.3% |
| Q2 2024 | Aug 30, 2024 · After close | −3.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Jun 14, 2024 · After close | −4.8% |
| Q4 2023 | Mar 29, 2024 · After close | +5.5% |
| Q3 2023 | Nov 9, 2023 · After close | +2.3% |
| Q2 2023 | Jul 31, 2023 · Before open | +2.8% |
| Q1 2023 | Jun 16, 2023 · After close | −1.0% |
| Q4 2022 | Mar 31, 2023 · After close | +1.9% |
| Q3 2022 | Dec 2, 2022 · After close | −1.4% |
| Q2 2022 | Aug 22, 2022 · Before open | +3.3% |
| Q1 2022 | May 27, 2022 · After close | +6.1% |
| Q3 2021 | Nov 19, 2021 · After close | −7.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (June 2026) | Investor deck | 25 slides | Jun 24, 2026 |
| Investor Presentation (June 2026) | Investor deck | 35 slides | June 2026 |
| Investor Presentation (March 2026) | Investor deck | 26 slides | Mar 24, 2026 |
| Enlivex Therapeutics — Investor Presentation (November 2025) | Investor deck | 26 slides | Nov 24, 2025 |
| Investor Presentation (November 2025) | Investor deck | 24 slides | November 2025 |
| Investor Presentation (November 2025) | Investor deck | 30 slides | November 2025 |
| Investor Presentation (October 2025) | Investor deck | 37 slides | October 2025 |
| Enlivex Therapeutics — Investor Presentation (September 2025) | Investor deck | 39 slides | September 2025 |
| Enlivex Therapeutics — Investor Presentation (August 2025) | Investor deck | 26 slides | Aug 18, 2025 |
| Enlivex Therapeutics — Investor Presentation (June 2025) | Investor deck | 39 slides | June 2025 |
All 32 decks
Financings
| Raise | Date |
|---|---|
| Registered direct offering of ordinary shares (or pre-funded warrants) with accompanying ordinary warrants Announced: US$7.5M · US$1.315 a share · Warrants at US$1.578 for 36 months Use of proceeds: Clinical, regulatory, manufacturing and R&D activities; potential acquisitions and in-licensing; general corporate purposes | Nov 16, 2026 |
| Private placement of ordinary shares Cancelled: US$400M · US$6 a share Buyers: Rain Foundation (66,666,667 ordinary shares, to be paid for using RAIN tokens (agreement terminated)) Use of proceeds: Treasury strategy built around the Rain protocol prediction markets, while continuing to advance its Allocetra immunotherapy for age-related osteoarthritis | Sep 22, 2026 |
| Private placement of ordinary shares (or ordinary share equivalents) Closed: US$212M raised · US$1 a share · BTIG Dealers: BTIG (lead) Use of proceeds: Implement a RAIN prediction markets token treasury strategy while continuing core business operations | Nov 26, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as BIO BLAST PHARMA LTD. Priced at US$11.00 a share on Jul 30, 2014.
- Price
- US$11.00 a share
- Shares offered
- 3,200,000 ordinary shares
- Offering size
- US$35.2 million
- Underwriters' option
- Up to 480,000 more shares
- Underwriters
- Oppenheimer & Co., Roth Capital Partners, BTIG · In the order on the cover
- Shares delivered
- On or about Aug 5, 2014
Steps
| Step | When |
|---|---|
| Filed publicly | Feb 7, 2014 |
| Amended 5 times | Newest Jul 25, 2014 |
| Shares registered with an exchange | Jul 28, 2014 |
| Declared effective by the SEC | Jul 30, 2014 |
| Final prospectus, with the price | Jul 31, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 31, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Jul 30, 2014 |
| EFFECT · Notice that a registration is effective | Jul 30, 2014 |
| CORRESP · Letter to the SEC | Jul 28, 2014 |
| CORRESP · Letter to the SEC | Jul 28, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 28, 2014 |
| CORRESP · Letter to the SEC | Jul 25, 2014 |
| F-1/A · Registration statement, amended | Jul 25, 2014 |
| UPLOAD · Letter from the SEC | Jul 24, 2014 |
| F-1/A · Registration statement, amended | Jul 15, 2014 |
All 18 filings
| Filing | Filed |
|---|---|
| F-1/A · Registration statement, amended | Jul 8, 2014 |
| F-1/A · Registration statement, amended | Apr 8, 2014 |
| CORRESP · Letter to the SEC | Apr 7, 2014 |
| UPLOAD · Letter from the SEC | Mar 27, 2014 |
| F-1/A · Registration statement, amended | Mar 17, 2014 |
| CORRESP · Letter to the SEC | Mar 14, 2014 |
| UPLOAD · Letter from the SEC | Mar 6, 2014 |
| F-1 · Registration statement | Feb 7, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 31, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 2.28M | 0 | 0 | 0 | 0 |
| Cost of revenue | 332.0K | 545.0K | 835.0K | 777.0K | 546.0K | 286.0K | 297.0K | 121.0K | 12.0K | 25.0K |
| Gross profit | -332.0K | -545.0K | -835.0K | -777.0K | -546.0K | -286.0K | -297.0K | -121.0K | -12.0K | -25.0K |
| Research and development | 9.20M | 10.6M | 19.0M | 18.7M | 12.9M | 6.09M | 5.60M | 4.01M | 1.69M | 8.88M |
| Selling, general and administrative | 5.68M | 4.91M | 6.14M | 6.70M | 6.24M | 3.60M | 2.75M | 937.0K | 2.96M | 6.99M |
| Operating income | -15.0M | -15.9M | -29.4M | -25.8M | -19.3M | -9.79M | -8.62M | -5.30M | -2.17M | -15.9M |
| Depreciation and amortization | 332.0K | 545.0K | 835.0K | 777.0K | 546.0K | 286.0K | 206.0K | 121.0K | 83.0K | 38.0K |
| EBITDA | -14.7M | -15.3M | -28.6M | -25.0M | -18.7M | -9.50M | -8.41M | -5.18M | -2.09M | -15.8M |
| Interest expense | 13.0K | 13.0K | 14.0K | 5.26M | 328.0K | 6.00K | 7.00K | 3.00K | 0 | 0 |
| Income before tax | 1.62B | -15.0M | -29.1M | -31.1M | 14.5M | 11.8M | 9.38M | -2.12M | -5.92M | -15.8M |
| Income tax | 382.6M | 4.24M | 11.3M | -4.82M | 2.04M | 765.0K | -4.00K | 28.0K | 216.0K | |
| Net income | 1.24B | -15.0M | -29.1M | -31.1M | -14.5M | -11.8M | -9.38M | -4.24M | -2.50M | -16.0M |
| Earnings per share, basic | 27.04 | -0.73 | -1.56 | -1.69 | -0.81 | -0.90 | -1.11 | -1.40 | -0.94 | -40.13 |
| Earnings per share, diluted | 25.48 | -0.73 | -1.56 | -1.69 | -0.81 | -0.90 | -1.11 | -1.40 | -0.94 | -40.13 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.89M | 3.30M | 813.0K | 49.9M | 11.2M | 5.67M | 3.95M | 9.74M | 9.03M | 3.04M |
| Short-term investments | 3.86M | 198.0K | 5.11M | 299.0K | 62.9M | 30.0M | 8.06M | 40.0K | 3.01M | |
| Receivables | 235.0K | 1.30M | 229.0K | 647.0K | 1.09M | 1.24M | 2.40M | 16.0K | 28.0K | 52.0K |
| Inventory | -229.0K | 1.18M | -12.2M | -31.2M | 1.50M | |||||
| Current assets | 1.74B | 26.0M | 33.8M | 52.3M | 86.4M | 38.1M | 16.4M | 10.3M | 3.62M | 10.5M |
| Property, plant and equipment | 361.0K | 625.0K | 1.54M | 9.88M | 2.53M | 1.48M | 648.0K | 685.0K | 388.0K | 71.0K |
| Total assets | 2.33B | 27.7M | 36.8M | 67.6M | 95.1M | 40.4M | 17.6M | 11.0M | 3.62M | 10.6M |
| Accounts payable | 3.81M | 811.0K | 827.0K | 1.95M | 878.0K | 463.0K | 316.0K | 173.0K | 19.0K | 32.0K |
| Current liabilities | 9.02M | 3.80M | 6.06M | 6.61M | 4.72M | 4.37M | 5.98M | 1.13M | 460.0K | 1.93M |
| Total debt | 641.0K | 534.0K | 1.03M | 4.85M | 6.01M | 203.0K | 123.0K | |||
| Total liabilities | 392.1M | 4.10M | 6.75M | 10.8M | 10.1M | 4.87M | 6.28M | 1.33M | 1.05M | 1.93M |
| Shareholders' equity | 1.93B | 23.6M | 30.1M | 56.8M | 85.0M | 35.5M | 11.3M | 9.71M | 8.49M | 2.81M |
| Shares outstanding | 237.4M | 23.7M | 18.6M | 18.4M | 18.3M | 14.6M | 10.3M | 3.51M | 418.5K | 3.28M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10.4M | -13.0M | -23.5M | -24.0M | -17.5M | -11.0M | -7.04M | -3.16M | -2.30M | -15.5M |
| Capital spending | -68.0K | -103.0K | -236.0K | -8.12M | -1.63M | -1.02M | -193.0K | -461.0K | -130.0K | -18.0K |
| Free cash flow | -10.5M | -13.1M | -23.8M | -32.1M | -19.2M | -12.0M | -7.23M | -3.62M | -2.43M | -15.5M |
| Cash from investing | -1.32M | 9.06M | -26.0M | 62.5M | -38.4M | -21.0M | -6.36M | -501.0K | -130.0K | 8.98M |
| Cash from financing | 10.4M | 6.45M | 360.0K | 150.0K | 61.0M | 33.1M | 8.31M | 5.19M | 8.05M | 6.09M |
| Share buybacks | 8.31M | 1.00K | 6.09M | |||||||
| Change in cash | -1.36M | 2.50M | -49.1M | 38.7M | 5.03M | 1.10M | -5.09M | 1.53M | 5.62M | -415.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 18, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 17, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 17, 2026 | Current report | SEC |
| 424B5 · Prospectus | Nov 17, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 28, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 27, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 22, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 19, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 424 filings. Open Filings
Cap table
Built by 6ix from Enlivex Ltd.’s releases · as of Nov 16, 2026
- Common shares
- 1,531,994
- Fully diluted
- 1,531,994
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,531,994 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,531,994 |
| Oct 22, 2026 | |
| Jul 7, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Roger Pomerantz Other companies: Indaptus Therapeutics, Inc. (Director · Since at least Sep 30, 2022); Viracta Therapeutics Inc (Director · May 25, 2022 – Nov 25, 2024 · Past) | Director · Since at least Mar 18, 2026 |
| Einat Galamidi | Chief Medical Officer · Since at least Oct 28, 2026 |
| Matteo Renzi | Director · Since at least Nov 24, 2025 |
| Oren Hershkovitz | Chief Executive Officer · Since at least Mar 18, 2026 |
| Shachar Shlosberger | Chief Financial Officer · Since at least Mar 18, 2026 |
| Shai Novik | Director · Since at least Mar 18, 2026 |
| Veronique Amor-Baroukh | Chief Operating Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Enlivex Ltd.